Regional circulatory distribution of novel cardiac bio-markers and their relationships with haemodynamic measurements.
暂无分享,去创建一个
J. Cleland | A. Clark | K. Goode | P. Pellicori | D. Ahmed | R. Nicholls
[1] Hans L Hillege,et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction , 2010, Annals of medicine.
[2] G. Rabinovich,et al. Galectins: structure, function and therapeutic potential , 2008, Expert Reviews in Molecular Medicine.
[3] J. Cleland,et al. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. , 2010, European heart journal.
[4] J. Struck,et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. , 2008, Journal of the American College of Cardiology.
[5] K. Miyamoto,et al. Endothelial cells actively synthesize and secrete adrenomedullin. , 1994, Biochemical and biophysical research communications.
[6] S. Anker,et al. The importance of the gastrointestinal system in the pathogenesis of heart failure. , 2005, European heart journal.
[7] Yigal M. Pinto,et al. Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction , 2004, Circulation.
[8] S. Yusuf,et al. Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study , 2006, Circulation.
[9] A. Hoes,et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.
[10] J. Struck,et al. Prognostic value of plasma midregional pro‐adrenomedullin and C‐terminal‐pro‐endothelin‐1 in chronic heart failure outpatients , 2009, European journal of heart failure.
[11] Daniel Levy,et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. , 2004, The New England journal of medicine.
[12] John G F Cleland,et al. Prognostic significance of ultrasound-assessed jugular vein distensibility in heart failure , 2015, Heart.
[13] J. Tardif,et al. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. , 1998, American heart journal.
[14] J. Cleland,et al. The in vitro stability of novel cardiovascular and sepsis biomarkers at ambient temperature , 2014, Clinical chemistry and laboratory medicine.
[15] Juerg Schwitter,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.
[16] T. Ishimitsu,et al. Clinical studies on the sites of production and clearance of circulating adrenomedullin in human subjects. , 1994, Hypertension.
[17] M. Assicot,et al. High serum procalcitonin concentrations in patients with sepsis and infection , 1993, The Lancet.
[18] N. Morgenthaler,et al. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States. , 2011, The Journal of clinical endocrinology and metabolism.
[19] S. Anker,et al. Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation. , 1999, International journal of cardiology.
[20] N. Freemantle,et al. Relationship between plasma concentrations of N‐terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP‐CHF study , 2012, European journal of heart failure.
[21] V. Hombach,et al. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end‐diastolic pressure , 1993, Clinical cardiology.
[22] Y. Wakiya,et al. Relationship between plasma atrial natriuretic peptide levels and atrial pressure in man. , 1986, The Journal of clinical endocrinology and metabolism.
[23] John G F Cleland,et al. Revisiting a classical clinical sign: jugular venous ultrasound. , 2014, International journal of cardiology.
[24] P. Ponikowski,et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial , 2012, European journal of heart failure.
[25] J. Cleland,et al. IVC diameter in patients with chronic heart failure: relationships and prognostic significance. , 2013, JACC. Cardiovascular imaging.
[26] L. Rochette,et al. P4243 | SPOTLIGHT 2013 Urinary and plasma galectin-3 in heart failure - insights in renal handling , 2013 .
[27] D. Stewart,et al. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. , 1996, Circulation.
[28] K. Kangawa,et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. , 1993, Biochemical and biophysical research communications.
[29] J. Cleland,et al. Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification? , 2013, The International Journal of Cardiovascular Imaging.